OGI ORGANIGRAM GLOBAL INC. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1620737 · Reporting currency CAD · Fiscal year ends 09/30
Financial factors as of 2022-08-31 (FY2022), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2024*2024-09-30 | FY2022*2022-08-31 |
|---|---|---|
| Income statement | ||
| Revenue | 159.84M | 145.81M |
| Cost of revenue | 111.39M | 119.04M |
| Gross profit | 47.52M | 31.57M |
| R&D expense | 11.20M | 5.96M |
| SG&A expense | 45.87M | 42.91M |
| Operating income | -35.67M | -43.15M |
| Interest expense | — | 429,000 |
| Pretax income | -45.44M | -14.37M |
| Income tax | 0 | -88,000 |
| Net income | -45.44M | -14.28M |
| EBITDA | -31.82M | -37.85M |
| EPS (basic) | -0.48 | -0.18 |
| EPS (diluted) | -0.48 | -0.18 |
| Weighted avg. shares (diluted) | 95.29M | 77.23M |
| Balance sheet | ||
| Cash & equivalents | 106.75M | 68.52M |
| Receivables | 37.15M | 46.37M |
| Inventory | 67.35M | 50.31M |
| Current assets | 262.22M | 221.62M |
| PP&E, netmay include right-of-use assets (IFRS) | 96.23M | 259.82M |
| Intangibles | — | 56.24M |
| Total assets | 407.86M | 577.11M |
| Current liabilities | 53.32M | 55.28M |
| Short-term debt | 60,000 | 80,000 |
| Long-term debt | 25,000 | 155,000 |
| Total debt | 85,000 | 235,000 |
| Total liabilities | 101.87M | 69.05M |
| Shareholders' equity | 305.99M | 508.06M |
| Net debt | -106.66M | -68.28M |
| Shares outstanding | 108.59M | 78.45M |
| Cash flow statement | ||
| Operating cash flow | 3.87M | -36.21M |
| Capital expenditure | 4.73M | 48.75M |
| Free cash flow | -859,000 | -84.96M |
| Investing cash flow | -38.77M | 44.03M |
| Financing cash flow | 107.78M | 5.33M |
| Depreciation & amortization | 3.85M | 5.30M |
| Stock-based compensation | 7.18M | 5.13M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.